

COST ACTION CA24124

1st Young Researchers Workshop/
Meeting &
2nd Working Groups Meeting

joint with

The 34th Local Liaison Physician
Meeting Of The European Branch
Of The Severe Chronic Neutropenia
International Registry (SCNIR)

KRAKOW, 03-05 September, 2026



KRAKOW, 03-05 September, 2026

Host: Prof Joanna Cichy and the Dept. of Immunology



Faculty of Biochemistry, Biophysics and Biotechnology (FBBB),
the Jagiellonian University, Krakow, Poland
Venue: Audytorium Maximum, Krupnicza 33 St.,
AGENDA outline (time zone local, CEST)

DAY 1

Thursday 03/09

YOUNG RESEARCHERS (YR) WORKSHOP

08:30 – 09:00

Registration

09:00 – 10:00

Introductory Sessions

- Welcome (H. Papadaki, C. Dufour, J. Cichy)
- Welcome and Presentation of Young NEUTRO-NARPS Group, Ice-breakers (V. Kargas, A. Skakic)

10:00 – 12:30

2 Sub-groups of YR sessions

Separate pre-defined groups of ECIs will try to work on preselected questions/queries on Chronic Neutropenias under the supervision of facilitators/tutors. Their findings and proposals will be presented and discussed on the third day of the Meeting.

(pre-registration will be needed among invited participants)

General moderators: V. Kargas, A. Skakic

Group 1: Congenital Neutropenia: a case based workshop focused on patient diagnosis, follow-up, novel and experimental therapies (e.g. CRISPR/gene therapy, iPS, etc)

Tutors: J. Skrzeczynska-Moncznik, A.-S. Hellmuth

Group 2: ACKR1/DARC-associated neutropenia (ADAN): a case based workshop focused on the diagnosis, follow-up, clinical significance, known data and unknown parameters of mechanisms leading to low ANC

Tutors: I. Pelagiadis, K. Pavlaki

12:30 – 14:00	Lunch Break
14:00 – 16:00	Meet-the-Expert Sessions (Chairs: H. Papadaki, J. Cichy, C. Dufour) - Erythroid ACKR1 Deficiency: From Genetic Loss to Downstream Effects and Their Mechanisms" (A. Rot) - How to establish a Neutropenia Clinic in 2026 (C. Dufour) - Microbiome–Inflammation–Neutrophil Axis in Acquired Chronic Neutropenia (I. Lagkouvardos) - What does your blood remember? The memory of hematopoietic stem cells" (K. Szade)
16:00 – 16:30	Coffee Break
16:30 – 18:00	Time allocated to Young Researchers for preparation of the presentation on Day 3

Networking dinner

DAY 2

Friday 04/09

WORKING GROUPS MEETING

07:30 – 08:00	Registration
08:00 – 09:00	WG-1 Session (Leaders: A. Warren, K. Welte, I. Touw, M. Bartels) - The role of ribosomal state in cell fate decisions and disease phenotypes (A. Warren) - Role of inflammation in clonal hematopoiesis in congenital neutropenias (J. Skokowa) - Clonal hematopoiesis in congenital neutropenias and Shwachman-Diamond-Syndrome (M. Klimiankou) - The evolving spectrum of congenital neutropenia syndromes: watch to learn (M. Bartels)

DAY 2

Friday 04/09

WORKING GROUPS MEETING

09:00 – 10:00

WG-2 Session

(Leaders: F. Fioredda, A. Eliopoulos, G. Tsaknakis)

- Last findings and next steps on Non-Remitting Neutropenia in children & Chronic Idiopathic Neutropenia in adults (F. Fioredda)
- Clinical Data Insights From Cypriot Neutropenic Patients (K. Pavlaki, P. Papasavva)
- Beyond Race: Can Duffy Phenotype Occur Across Diagnoses and Relate to Blood Counts in Chronic Neutropenia? (R. Cerqueira)
- Exploring the Diet–Inflammation Axis in Chronic Neutropenia (A. Eliopoulos)

10:00 – 10:30

Coffee break

10:30 – 11:30

WG-3 Session

(Leaders: H. Latsoudis, G. Cavalca)

- Demo on the Neutro-NARPS Information Management System Prototype (N. Angeli, V. Tzikoulis)
- Significance of the data sharing and integration for the IMS development and Chronic Neutropenia risk factor profiling. (H. Latsoudis, G. Manikis)

11:30 – 12:30

WG-4 Session

(Leaders: C. Simoglou Karali, M. Spanoudakis, A. Pierini)

- Multimodal Evaluation of Drug-Induced Neutropenia: Integration of Haematologic, Genomic, and Cytometry-Based Profiling (C. Simoglou Karali)
- Teaching AI the Regulatory Code: From DNA sequence to cell type Towards applications in neutropenia (S. Riva)

DAY 2

Friday 04/09

WORKING GROUPS MEETING

12:30 – 13:30 **Lunch break**

13:30 – 14:30 **WG-5 Session**
(Leaders: J. Skokowa, J. Cichy, V. Bezzerri)

- New therapeutic opportunities for severe congenital neutropenia (J. Skokowa)
- Serine Proteases and Their Regulators in iPSC-Based Studies of Neutropenia (J. Cichy)
- Update on Translational Readthrough-Inducing Drug Development in Inherited Bone Marrow Failure Syndromes (A. M. Hristodor)

14:30 – 15:30 **WG-6 Session**
(Leaders: C. Zeidler, C. Karamanidou, E. Laane)

- Quality of Life assessment (S. Salek)
- Update on the literature search (C. Karamanidou)
- Suggestions for a QoL assessment for patients with chronic neutropenia (C. Zeidler)
- Progress in the EHA SWG on QoL and possible interaction with the Neutro-NARPS (E. Laane)

Guided Tour
Networking dinner



DAY 3

Saturday 05/09

PARALLEL SESSIONS

YOUNG RESEARCHERS (YR) MEETING

08:00 – 09:00

Oral presentations of abstracts

(Chairs: M. Klimiankou, J. Skrzeczyńska, O. Steinberg-Shemer)

- PROTAC-mediated Degradation of Neutrophil Elastase Reveals ERAD Activation in ELANE-related Neutropenia (V. Makaryan)
- Modeling ELANE-Associated Congenital Neutropenia Using iPSC Lines with Modified Elafin Expression (K. Gajewski)
- Neutropenia-associated alterations in adipose tissue remodeling during psoriatic skin inflammation (I. Sinkevich)
- Genetic Landscape of Congenital Neutropenia and Neutropenia-Associated Bone Marrow Failure Syndromes in the Polish Slavic Cohort (G. Chabrzyk)
- Descriptor-Guided Explainable QSAR Model for Predicting Drug-Induced Neutropenia Risk and Supporting Toxicity-Aware Molecular Optimization (G. Karaduman)

09:00 – 10:30

Poster Walk

Moderators: (V. Tomacinschii, A. Mazur, R. Cerqueira)

10:30 – 10:45

Coffee break

10:45 – 11:45

Presentations of Young sub-groups from Day 1

(Chairs: A. Skakic, V. Kargas)

11:45 – 12:15

JOINT EHA & NEUTRO-NARPS Session

(Chairs: H. Papadaki, C. Dufour)

The EHA/Neutro-NARPS interaction (V. Lotushko)

DAY 3

Saturday 05/09

PARALLEL SESSIONS

YOUNG RESEARCHERS (YR) MEETING

12:15 – 13:45

Neutro-NARPS Partners and Industry session

(Chairs: H. Papadaki, C. Dufour, J.Cichy)

- RARE Diseases ORG Greece (K. Theochari)
- Results of survey of Diversity/Inclusion/Equality Team (A. Catic-Djordjevic)
- Seeing More, Discovering More: An Introduction to Full Spectrum Profiling (E. Swart)
- The Ongoing Development of Mavorixafor in the Treatment of WHIM Syndrome and Chronic Neutropenia (K. Adell)

13:45 – 14:45

Lunch break

PARALLEL SESSIONS:

LOCAL LIAISON PHYSICIANS (LLP) MEETING OF THE EUROPEAN BRANCH OF THE SEVERE CHRONIC NEUTROPENIA INTERNATIONAL REGISTRY (SCNIR)

09:30 – 19:00

LLP – SCNIR Meeting



SPEAKER/ WG-LEADER/ TUTOR *			INSTITUTION of AFFILIATION	COUNTRY of AFFILIATION
Dr	Katrina	Adell	Medical Director, Clinical Development, X4 Pharmaceuticals Inc, Boston MA	USA
Ms	Natalia	Angeli	School of Medicine, University of Crete	Greece
Dr	Marije	Bartels	Department of Pediatric Hematology, University Medical Center Utrecht, Utrecht	the Netherlands
Prof	Valentino	Bezzetti	Department of Life Sciences, Health, and Health Professions, Link Campus University, Rome ; Cystic Fibrosis Center, Azienda Ospedaliera Universitaria Integrata, Verona	Italy
Prof	Aleksandra	Catic Djordjevic	Department of Pharmacy, Faculty of Medicine, University of Nis	Serbia
Dr	Giacomo	Cavalca	Clinical Bioinformatics Unit, IRCCS Istituto Giannina Gaslini , Genoa; Alma Mater Studiorum – University of Bologna, Bologna	Italy
Dr	Renato	Cerqueira	Department of Clinical and Experimental Oncology, Federal University of São Paulo (UNIFESP), Sao Paulo	Brazil
Ms	Gabriela	Chabrzyk	Department of Pediatrics, Oncology and Hematology, Medical University of Lodz, Lodz	Poland
Prof	Joanna	Cichy	Department of Immunology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków	Poland
Dr	Carlo	Dufour	Unit of Hematology-IRCCS Istituto Giannina Gaslini, Genoa	Italy
Prof	Aristidis	Eliopoulos	Medical School, National and Kapodistrian University of Athens, Athens	Greece
Dr	Francesca	Fiorredda	Unit of Hematology-IRCCS Istituto Giannina Gaslini, Genoa	Italy
Mr	Kacper	Gajewski	Department of Immunology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow	Poland
Ms	Anna-Sophia	Hellmuth	Department of Oncology, Hematology, Clinical Immunology, and Rheumatology, University Hospital Tuebingen, Tuebingen	Germany
Ms	Anca Manuela	Hristodor	Cystic Fibrosis Center, Azienda Ospedaliera Universitaria Integrata, Verona	Italy
Dr	Gül	Karaduman	Karamanoglu Mehmetbey University, Department of Mathematics, Karaman ; The University of Texas at Arlington, Department of Mathematics, Arlington, TX	Turkiye /USA
Dr	Christina	Karamanidou	Institute of Applied Biosciences, Centre for Research & Technology-Hellas, Thessaloniki	Greece
Dr	Vassilis	Kargas	Cambridge Institute for Medical Research, University of Cambridge, Cambridge	UK
Dr	Maksim	Klimiankou	Department of Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tübingen; Faculty of Medicine University Tübingen, Gene and RNA Therapy Center (GRTC), Tübingen; Severe Chronic Neutropenia International Registry, SCNIR, Hannover	Germany
Dr	Edward	Laane	Hematology-Oncology Clinic, Tartu University, Tartu	Estonia
Prof	Ilias	Lagkouvardos	Department of Clinical Microbiology, School of Medicine, University of Crete, Heraklion	Greece
Dr	Helen	Latsoudis	Information Systems Laboratory (ICS), Institute of Computer Science, Foundation for Research and Technology Hellas (FORTH); Haemopoiesis Research Lab, School of Medicine, University of Crete, Heraklion	Greece
Mr	Volodymyr	Lotushko	Specialized Working Group (SWG) Manager, European Hematology Association (EHA)	the Netherlands
Dr	Vahagn	Makaryan	Department of Medicine, University of Washington, Seattle, WA	USA
Prof	Georgios	Manikis	Associate Professor, Department of Electrical & Computer Engineering, Hellenic Mediterranean University, Heraklion, Crete; Collaborating researcher, Computational Biomedicine Laboratory(CBML), Institute of Computer Sciences(ICS), Foundation for Research and Technology (FORTH), Heraklion, Crete	Greece
Dr	Angelika	Mazur	Department of Immunology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow	Poland
Prof	Helen	Papadaki	Haemopoiesis Research Laboratory, University of Crete, Heraklion; Hematology Department, University Hospital of Heraklion, Heraklion	Greece
Dr	Panayiota	Papasavva	Department of Molecular Genetics Thalassemia, The Cyprus Institute of Neurology & Genetics, Nicosia; Cyprus School of Molecular Medicine, Nicosia	Cyprus
Dr	Konstantia	Pavlaki	German Medical Institute, Lemesos	Cyprus
Prof	Iordanis	Pelagiadis	Pediatric Hematology-Oncology Department, University of Crete, Heraklion; University Hospital of Heraklion, Heraklion	Greece
Prof	Antonio	Pierini	Hematology and Clinical Immunology Section, Center for Hemato-Oncology Research, Department of Medicine and Surgery, University of Perugia, Perugia	Italy
Dr	Simone	Riva	MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford; MRC WIMM Centre for Computational Biology, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford	UK
Prof	Antal	Rot	Faculty of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, London	UK

SPEAKER/ WG-LEADER/ TUTOR *			INSTITUTION of AFFILIATION	COUNTRY of AFFILIATION
Dr	Sam	Salek	School of Life and Medical Sciences, University of Hertfordshire, Hatfield	UK
Dr	Christina	Simoglou Karali	Department of Biology, School of Medicine, National and Kapodistrian University of Athens, Athens; Medical Research Council Weatherall Institute of Molecular Medicine (MRC WIMM) and NIHR Biomedical Research Centre Hematology Theme, University of Oxford, Oxford	Greece/UK
Mr	Ivan	Sinkevich	Department of Immunology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków; Doctoral School of Exact and Natural Sciences, Jagiellonian University, Krakow	Poland
Prof	Anita	Skacic	Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade	Serbia
Prof	Julia	Skokowa	Department of Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tübingen; Faculty of Medicine University Tübingen, Gene and RNA Therapy Center (GRTC), Tübingen; Severe Chronic Neutropenia International Registry, SCNIR, Hannover	Germany
Dr	Joanna	Skrzeczynska -Moncznik	Research Scientist, Jagiellonian University, Krakow	Poland
Dr	Michail	Spanoudakis	Department of Haematology, Warrington and Halton Teaching Hospitals NHS Foundation Trust, Cheshire	UK
Dr	Orna	Steinberg – Shemer	Faculty of Medicine, Tel Aviv University, Tel Aviv; Pediatric Hematology Laboratory, Felsenstein Medical Research Center, Petach Tikva	Israel
Dr	Erwin	Swart	Cytek BioSciences	The Netherlands
Prof	Krzysztof	Szade	Laboratory of Stem Cell Biology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow	Poland
Ms	Kate	Theochari	Vice President B Rare Diseases Greece -Chairperson Greek Lysosomal Association, Athens	Greece
Prof	Victor	Tomacinschii	Department of Hematology, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau; Department of Hematology, Public Medical Sanitary Institution (PMSI) Institute of Oncology, Chisinau	Republic of Moldova
Prof	Ivo	Touw	Department of Hematology, Erasmus Medical Center Cancer Institute, Erasmus University Medical Center, Rotterdam	the Netherlands
Dr	Grigorios	Tsaknakis	Haemopoiesis Research Lab, School of Medicine, University of Crete, Heraklion	Greece
Mr	Vassilis	Tzikoulis	Information Systems and Applications Department, Digital Governance Unit, University of Crete, Heraklion	Greece
Prof	Alan	Warren	Cambridge Institute for Medical Research, Cambridge Biomedical Campus, Cambridge and Department of Haematology, University of Cambridge School of Clinical Medicine, Cambridge	UK
Prof	Karl	Welte	Department of Pediatric Hematology, Oncology and Bone Marrow Transplantation, Children's Hospital, University Hospital Tübingen, Tübingen, and Severe Chronic Neutropenia International Registry, SCNIR, Hannover	Germany
Dr	Cornelia	Zeidler	Severe Chronic Neutropenia International Registry, SCNIR, Hannover & Department of Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tübingen	Germany

*In alphabetical order

How can I participate?

Visit: www.neutro-narps.eu/how-can-i-participate
(or scan the QR)

- Read the Action Description MoU
- Inform the Chair (e.papadaki@uoc.gr)
- Apply to join your Working Group



Please note: Management Committee nominations are carried out through the COST National Coordinators



Neutro-NARPS | CA24124

Network for the Advancement of Neutropenia Research and Patient Support

 coordinator@neutro-narps.eu

 www.neutro-narps.eu

 facebook.com/neutro.narps

 x.com/neutronarps

 linkedin.com/company/neutronarps



This article/publication is based upon work from COST Action CA24124, supported by COST (European Cooperation in Science and Technology).

COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. Our Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation.

www.cost.eu